Chardan将Dicerna PharmPharmticals的评级从买入下调至中性，诺和诺德拟议的收购将PT从28美元调整至38.25美元

10:28 AM EST, 12/09/2021 (MT Newswires) -- Dicerna Pharmaceuticals (DRNA) has an average hold rating and a price target range of $36 to $38.25, according to analysts polled by Capital IQ.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: )

Price: 38.07, Change: +0.07, Percent Change: +0.18